Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver

J Lipid Res. 2018 Dec;59(12):2349-2359. doi: 10.1194/jlr.M089250. Epub 2018 Oct 28.

Abstract

Dietary fat absorption takes place in the intestine, and the liver mobilizes endogenous fat to other tissues by synthesizing lipoproteins that require apoB and microsomal triglyceride transfer protein (MTP). Dietary fat triggers the synthesis of oleoylethanolamide (OEA), a regulatory fatty acid that signals satiety to reduce food intake mainly by enhancing neural PPARα activity, in enterocytes. We explored OEA's roles in the assembly of lipoproteins in WT and Ppara-/- mouse enterocytes and hepatocytes, Caco-2 cells, and human liver-derived cells. In differentiated Caco-2 cells, OEA increased synthesis and secretion of triacylglycerols, apoB secretion in chylomicrons, and MTP expression in a dose-dependent manner. OEA also increased MTP activity and triacylglycerol secretion in WT and knockout primary enterocytes. In contrast to its intestinal cell effects, OEA reduced synthesis and secretion of triacylglycerols, apoB secretion, and MTP expression and activity in human hepatoma Huh-7 and HepG2 cells. Also, OEA reduced MTP expression and triacylglycerol secretion in WT, but not knockout, primary hepatocytes. These studies indicate differential effects of OEA on lipid synthesis and lipoprotein assembly: in enterocytes, OEA augments glycerolipid synthesis and lipoprotein assembly independent of PPARα. Conversely, in hepatocytes, OEA reduces MTP expression, glycerolipid synthesis, and lipoprotein secretion through PPARα-dependent mechanisms.

Keywords: apolipoprotein B; chylomicrons; microsomal triglyceride transfer protein; oleic acid; peroxisome proliferator-activated receptor alpha; very low density lipoprotein.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Caco-2 Cells
  • Carrier Proteins / metabolism
  • Cell Line, Tumor
  • Cholesterol, VLDL / metabolism
  • Dietary Fats / adverse effects
  • Endocannabinoids / pharmacology*
  • Enterocytes / drug effects
  • Enterocytes / metabolism
  • Hep G2 Cells
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism
  • Humans
  • Intestines / drug effects*
  • Lipid Metabolism / drug effects
  • Lipoproteins / metabolism*
  • Liver / drug effects
  • Liver / metabolism*
  • Mice
  • Oleic Acids / pharmacology*
  • PPAR alpha / metabolism

Substances

  • Carrier Proteins
  • Cholesterol, VLDL
  • Dietary Fats
  • Endocannabinoids
  • Lipoproteins
  • Oleic Acids
  • PPAR alpha
  • microsomal triglyceride transfer protein
  • oleoylethanolamide